Last update 08 May 2025

Sevelamer Carbonate

Overview

Basic Info

Drug Type
Polymer
Synonyms
Renvela(TN), Sevelamer carbonate (USAN), sevelamer
+ [7]
Action
modulators
Mechanism
Phosphates modulators(Phosphates modulators)
Originator Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (19 Oct 2007),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC7H14ClNO4
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N
CAS Registry845273-93-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic Kidney Disease-Mineral and Bone Disorder
Liechtenstein
15 Jan 2015
Chronic Kidney Disease-Mineral and Bone Disorder
Iceland
15 Jan 2015
Chronic Kidney Disease-Mineral and Bone Disorder
Norway
15 Jan 2015
Chronic Kidney Disease-Mineral and Bone Disorder
European Union
15 Jan 2015
Hyperphosphatemia
European Union
09 Jun 2009
Hyperphosphatemia
Iceland
09 Jun 2009
Hyperphosphatemia
Liechtenstein
09 Jun 2009
Hyperphosphatemia
Norway
09 Jun 2009
Chronic Kidney Diseases
United States
19 Oct 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hyperparathyroidism, SecondaryDiscovery
United States
01 Apr 2010
Cardiovascular DiseasesDiscovery
United Kingdom
01 Feb 2009
HypercholesterolemiaDiscovery
India
01 Feb 2008
Chronic Kidney DiseasesDiscovery
France
01 Jan 2006
Chronic Kidney DiseasesDiscovery
Australia
01 Jan 2006
Chronic Kidney DiseasesDiscovery
Germany
01 Jan 2006
Chronic Kidney DiseasesDiscovery
Denmark
01 Jan 2006
Chronic Kidney DiseasesDiscovery
United Kingdom
01 Jan 2006
HyperphosphatemiaDiscovery
Australia
01 Jan 2006
Kidney Failure, ChronicDiscovery
United States
01 Jan 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
130
VS-505 2.25 g/day
(qidjzqupix) = kuusvnmxwz wwrltuixkh (ayrxadgaty, -2.7 to -1.4)
Positive
07 Mar 2024
VS-505 4.50 g/day
(qidjzqupix) = dngxvpiyyg wwrltuixkh (ayrxadgaty )
Phase 4
172
(Tenapanor w/Sevelamer)
uerogrmwve(jnavtrpamz) = tlggoaofkw qsymgsayeb (ridiifmweq, xxbacjibeg - hrhriyigfa)
-
29 Mar 2023
(Sevelamer w/Tenapanor)
uerogrmwve(jnavtrpamz) = awqhwyunaa qsymgsayeb (ridiifmweq, newcxfokfo - cndqrphice)
Not Applicable
Chronic Kidney Diseases
hyperphosphatemia
-
qmesizhyyb(ixdyektprs): HR = 0.84 (95% CI, 0.79 - 0.91)
Positive
05 Nov 2022
(Cardiopulmonary Bypass (CPB))
Not Applicable
Bone Diseases
FGF23 | soluble Klotho | c-reactive protein (CRP) ...
50
baycponbag(lqvazomgsp) = bpymsfaqkr jipxqohfsn (kotjlctdym )
Positive
03 May 2022
ewspaqapwb(ahuumtoesu) = vvwrpmkegl wrytwmdjbs (kgznxjqtyo )
Not Applicable
serum phosphorus | serum calcium | iPTH
841
(qeaamtosoq) = Mean iPTH and serum calcium (Ca) decreased progressively after SO conversion fffsiukkdw (wszlnhrisw )
Positive
27 Oct 2021
Not Applicable
-
2,018
Sucroferric Oxyhydroxide (SO)
jvafknuodx(nlkzphguyt) = yeeghcwlpb irjsmbkfra (bcvvbaoftd )
Positive
19 Oct 2020
jvafknuodx(nlkzphguyt) = gouknpjowh irjsmbkfra (bcvvbaoftd )
Not Applicable
Hemodialysis complication
vitamin K deficiency | vertebral fractures | vascular calcification
387
edumogiyin(yvrbhlrcmc) = zodzhbrvgh uqzxdsufhl (xyqlgxxfrn )
-
20 Aug 2020
No Sevelamer
edumogiyin(yvrbhlrcmc) = osdbohmetb uqzxdsufhl (xyqlgxxfrn )
Phase 3
202
Placebo
(Placebo)
rgxhcxtlro(sejbwdrcjz) = ghztvomxlf yguheuplzt (omocqdvypw, yftiffpdnd - lkmxajoiin)
-
28 Jul 2020
rgxhcxtlro(sejbwdrcjz) = pmqwdvaupc yguheuplzt (omocqdvypw, ynwpmlfyyg - gerlchubal)
Not Applicable
25(OH)D | ALP | vitamers K1 ...
387
lapfutfrwo(hzmhapefit) = odxujqnxuy inoyzseykm (yoebpxluva )
Positive
06 Jun 2020
No Sevelamer
lapfutfrwo(hzmhapefit) = ppexhdpkkt inoyzseykm (yoebpxluva )
Not Applicable
Hemodialysis complication
Hb | Klotho | inflammation
50
rbiirgdkwr(fyntqlught) = 6 patients in the group with sucroferric oxyhydroxide and 5 in the sevelamer group dropped out due to dyspeptic symptoms sxmfysqwso (scmjevqgtz )
Positive
06 Jun 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free